Artelo Biosciences jumps as it plans UK study of glaucoma drug

Shares of biotech firm Artelo Biosciences ARTL.O rise 55% to $7.35 premarket

Co says it will test experimental cannabinoid drug, ART27.13, in glaucoma, an eye disease that damages vision by raising pressure inside the eye

Says study in the UK will see if the oral capsule can safely lower eye pressure in people with glaucoma or ocular hypertension, a condition with higher‑than‑normal eye pressure

Trial funded by Glaucoma UK and HSC R&D; patient enrolment to start in Q2 2026, co says

Drug is designed to work outside the brain to avoid “high” or mind‑altering effects, co says

ART27.13 is also being tested for cancer‑related weight loss; co says glaucoma study could expand its use - ARTL

Shares down ~81% in 2025